ProCE Banner Activity

Smarter. Stronger. Together: Educating Providers and Patients to Optimize the Use of Targeted Oral Therapies for HR+/HER2- Breast Cancer

Slideset Download

Download these slides from a live Webinar to gain expert insight on the new and emerging data on the optimal use of CDK4/6 and PI3K inhibitors for patients with HR+/HER2 breast cancer.

Resources for your patients: https://www.smartpatients.com/resources/cco-breast-cancer

Released: March 05, 2021

Expiration: March 04, 2022

Share

Faculty

Matthew P. Goetz

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California

Supporters

Supported by an educational grant from

Lilly

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Matthew P. Goetz, MD

Professor of Oncology and Pharmacology
Director, Mayo Breast Cancer SPORE
Co-PI, Womens Cancer Program
Department of Medical Oncology
Mayo Clinic
Rochester, Minnesota

Sara Hurvitz, MD

Assistant Professor of Medicine
Director, Breast Oncology Program
Division of Hematology-Oncology
Department of Internal Medicine
David Geffen School of Medicine at UCLA
Los Angeles, California